Novel GLP-1 Analog APT3711

—

APT3711, a GLP-1 peptide analog, demonstrates an extended half-life relative to semaglutide.

APT3711 has the potential to be (i) an oral, once-weekly treatment for obesity and diabetes, and (ii) a once-a-month injection for obesity and type 2 diabetes, offering meaningful advantages over Semaglutide and Tirzepatide, both of which require once-weekly injections.

Key preclinical findings:

●  In rat, APT 3711 has a half-life 62% longer than Semaglutide and 45% longer than Tirzepatide.

●  In minipigs, APT3711 demonstrated 2.7-fold longer half-life compared with Semaglutide.

●  In diet-induced obese (DIO) mice, APT 3711 achieved anti-obesity efficacy comparable to Semaglutide.

Development potential:

●  A once-monthly injectiable therapy for obesity and T2DM, superior to once-weekly injectable Semaglutide.

●  An oral, once-weekly treatment for obesity and diabetes.

 The global GLP-1 market is projected to exceed $100 billion in annual sales, positioning APT3711 as a compelling opportunity within a rapidly expanding therapeutic area. 

The half-life of APT3711 in minipig is superior (2.7-fold) to that of Semaglutide

●  Animals: Male Bama minipigs.

●  Dose: 12.1 nmol/kg

●  Administration: Single SC

●  Time points: 0-384 hours

The weight loss activity of APT 3711 and Semaglutide was comparable at 5 nmol/kg daily dose.

●  Animals: Male DIO Mice

●  Daily dose: 5 nmol/kg

Contact: Simrat Singh, COO simrat.singh@ampeptec.com